These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
3. Febrile neutropenia: highlighting the role of prophylactic antibiotics and granulocyte colony-stimulating factor during standard dose chemotherapy for solid tumors. Timmer-Bonte JN; Tjan-Heijnen VC Anticancer Drugs; 2006 Sep; 17(8):881-9. PubMed ID: 16940798 [TBL] [Abstract][Full Text] [Related]
4. Cost-effectiveness of adding granulocyte colony-stimulating factor to primary prophylaxis with antibiotics in small-cell lung cancer. Timmer-Bonte JN; Adang EM; Smit HJ; Biesma B; Wilschut FA; Bootsma GP; de Boo TM; Tjan-Heijnen VC J Clin Oncol; 2006 Jul; 24(19):2991-7. PubMed ID: 16682725 [TBL] [Abstract][Full Text] [Related]
5. Prophylactic administration of granulocyte colony-stimulating factor (filgrastim) after conventional chemotherapy in children with cancer. Riikonen P; Rahiala J; Salonvaara M; Perkkiö M Stem Cells; 1995 May; 13(3):289-94. PubMed ID: 7542114 [TBL] [Abstract][Full Text] [Related]
6. Effects of a formulary change from granulocyte colony-stimulating factor to granulocyte-macrophage colony-stimulating factor on outcomes in patients treated with myelosuppressive chemotherapy. Wong SF; Chan HO Pharmacotherapy; 2005 Mar; 25(3):372-8. PubMed ID: 15843284 [TBL] [Abstract][Full Text] [Related]
7. Cost effectiveness of primary pegfilgrastim prophylaxis in patients with breast cancer at risk of febrile neutropenia. Aarts MJ; Grutters JP; Peters FP; Mandigers CM; Dercksen MW; Stouthard JM; Nortier HJ; van Laarhoven HW; van Warmerdam LJ; van de Wouw AJ; Jacobs EM; Mattijssen V; van der Rijt CC; Smilde TJ; van der Velden AW; Temizkan M; Batman E; Muller EW; van Gastel SM; Joore MA; Borm GF; Tjan-Heijnen VC J Clin Oncol; 2013 Dec; 31(34):4283-9. PubMed ID: 24166522 [TBL] [Abstract][Full Text] [Related]
8. The prevention of febrile neutropenia. Pascoe J; Cullen M Curr Opin Oncol; 2006 Jul; 18(4):325-9. PubMed ID: 16721125 [TBL] [Abstract][Full Text] [Related]
9. When the risk of febrile neutropenia is 20%, prophylactic colony-stimulating factor use is clinically effective, but is it cost-effective? Adams JR; Angelotta C; Bennett CL J Clin Oncol; 2006 Jul; 24(19):2975-7. PubMed ID: 16682722 [No Abstract] [Full Text] [Related]
10. [A randomized double-blind controlled study of recombinant human granulocyte colony-stimulating factor in patients with neutropenia induced by consolidation chemotherapy for acute myeloid leukemia. (rG.CSF clinical study group)]. Takeshita A; Ohno R; Hirashima K; Toyama K; Okuma M; Saito H; Ikeda Y; Tomonaga M; Asano S Rinsho Ketsueki; 1995 Jun; 36(6):606-14. PubMed ID: 7543956 [TBL] [Abstract][Full Text] [Related]
11. Chemoprophylaxis with oral ciprofloxacin in ovarian cancer patients receiving taxol. Carlson JW; Fowler JM; Saltzman AK; Carter JR; Chen MD; Mitchell SK; Dunn D; Carson LF; Adcock LL; Twiggs LB Gynecol Oncol; 1994 Dec; 55(3 Pt 1):415-20. PubMed ID: 7530677 [TBL] [Abstract][Full Text] [Related]
12. Prevention of chemotherapy-induced febrile neutropenia by prophylactic antibiotics plus or minus granulocyte colony-stimulating factor in small-cell lung cancer: a Dutch Randomized Phase III Study. Timmer-Bonte JN; de Boo TM; Smit HJ; Biesma B; Wilschut FA; Cheragwandi SA; Termeer A; Hensing CA; Akkermans J; Adang EM; Bootsma GP; Tjan-Heijnen VC J Clin Oncol; 2005 Nov; 23(31):7974-84. PubMed ID: 16258098 [TBL] [Abstract][Full Text] [Related]
13. Use of decision analysis to evaluate the costs and benefits of filgrastim (G-CSF) therapy. Peroutka JA; Mutnick AH Formulary; 1995 Jul; 30(7):394-5, 400-4. PubMed ID: 10151731 [TBL] [Abstract][Full Text] [Related]
14. [Guidelines for prevention of febrile neutropenia]. Barroso S; Damasceno M; Dinis J; Gervásio H; da Luz R; Passos-Coelho JL; Sá A; Costa L; Rodrigues H; Andrade S; Macedo A; Moital I Acta Med Port; 2008; 21(1):7-19. PubMed ID: 18489831 [TBL] [Abstract][Full Text] [Related]
15. Neutropenic complications in advanced-stage non-Hodgkin's lymphoma: implications for the use of prophylactic recombinant human granulocyte-colony stimulating factor (G-CSF). Bobey N; Woodman RC Clin Invest Med; 1998 Apr; 21(2):63-70. PubMed ID: 9562926 [TBL] [Abstract][Full Text] [Related]
16. Economic evaluation of prophylactic granulocyte colony stimulating factor during chemotherapy in elderly patients with aggressive non-Hodgkin's lymphoma. Doorduijn JK; Buijt I; van der Holt B; van Agthoven M; Sonneveld P; Uyl-de Groot CA Haematologica; 2004 Sep; 89(9):1109-17. PubMed ID: 15377472 [TBL] [Abstract][Full Text] [Related]
17. [Effect of recombinant human granulocyte colony-stimulating factor (rG-CSF) on chemotherapy-induced neutropenia in patients with lung cancer]. Ohnoshi T; Ueoka H; Kodani T; Kamei H; Kimura I Gan To Kagaku Ryoho; 1990 Apr; 17(4 Pt 2):911-8. PubMed ID: 1693062 [TBL] [Abstract][Full Text] [Related]
18. The clinical utility of granulocyte colony-stimulating factor: early achievements and future promise. Morstyn G; Foote M; Perkins D; Vincent M Stem Cells; 1994; 12 Suppl 1():213-27; discussion 227-8. PubMed ID: 7535147 [TBL] [Abstract][Full Text] [Related]
19. Granulocyte colony-stimulating factors in the management of chemotherapy-induced neutropenia: evidence based review. Bhana N Curr Opin Oncol; 2007 Jul; 19(4):328-35. PubMed ID: 17545795 [TBL] [Abstract][Full Text] [Related]
20. Randomized comparison of antibiotics with and without granulocyte colony-stimulating factor in children with chemotherapy-induced febrile neutropenia: a report from the Children's Oncology Group. Ozkaynak MF; Krailo M; Chen Z; Feusner J Pediatr Blood Cancer; 2005 Sep; 45(3):274-80. PubMed ID: 15806544 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]